Transient Tumor Microbiome Engineering: Leveraging Intratumoral Escherichia for Enhanced Checkpoint Inhibitor Response

Recent work (Source: Elkrief et al., 2023, Cancer Research) found that the presence of intratumoral Escherichia correlates with better outcomes to checkpoint therapy in NSCLC. While the tumor microbiome’s role is emerging, the idea of intentionally and transiently modifying the tumor microbiome to induce a pro-inflammatory state is unexplored. This research would involve engineering bacteria to survive briefly in the tumor, deliver danger signals, and then be cleared—avoiding long-term infection risks. It builds on the concept of microbiome modulation (Said & Ibrahim, 2025) but applies it at the tumor site, potentially converting non-responders to responders. This approach could pioneer a new class of adjuvant therapies for immunologically “cold” tumors.

References:

1. Abstract 5185: Intratumoral Escherichia is associated with response to single-agent immune checkpoint inhibition in patients with advanced non-small cell lung cancer. A. Elkrief, A. Bowman, Ayyüce Begüm Bektas, Wenfei Kang, K. Manova-Todorova, J. Egger, H. Rizvi, D. Kelly, E. Chan, Eric Rosiek, Fan Ning, Gregory Riely, Álvaro Quintanal Villalonga, S. Dogan, U. Bhanot, M. Gonen, M. Hellmann, A. Schoenfeld, C. Rudin, M. Ladanyi, Chad M. Vanderbilt (2023). Cancer Research.
2. Gut Microbiota–Tumor Microenvironment Interactions: Mechanisms and Clinical Implications for Immune Checkpoint Inhibitor Efficacy in Cancer. S. Said, W. N. Ibrahim (2025). Cancer Management and Research.